Syndax Pharmaceuticals Inc
Healthcare · EUR · F
Price
€16.808
Cap
€1.90B
Earnings
—
30d Trend
-14.9%
BRAIN47 SIGNAL
Raw weighted: 46×Macro 0.99 (−1%)=46
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
Medium-term outlook is neutral — no clear directional thesis
BRAIN47'S ASSESSMENT
I rate Syndax Pharmaceuticals Inc at 46/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 77/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
DETAILED ANALYSIS
Medium-term outlook is neutral — no clear directional thesis. Momentum (77) and Technical (53) are the primary strengths. I note that quality is the weakest area at 15/100 — this warrants monitoring. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.